594865-06-2 Usage
Molecular Structure
1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-methyl-6-(methylthio)-N-[(4-nitrophenyl)methyl]contains a pyrazolopyrimidine core structure, which is a fused ring system consisting of a pyrazole and a pyrimidine ring.
Substituents
The compound has a methyl group attached to the 1-position, a methylthio group at the 6-position, and a 4-nitrophenylmethyl group attached to the nitrogen atom.
Basicity
The compound contains an amino group (-NH2) at the 4-position, which can act as a base and form salts with acids.
Potential Pharmacological Properties
Due to its unique structure and substituents, 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-methyl-6-(methylthio)-N-[(4-nitrophenyl)methyl]may exhibit enzyme inhibitory or receptor binding properties, making it a potential candidate for drug development and medicinal chemistry.
Biological Activities
The specific biological activities of this compound are not yet known and would require further research and testing to determine its potential therapeutic applications.
Investigation and Testing
To fully understand the properties and potential applications of this compound, further research and testing would be needed, including in vitro and in vivo studies to evaluate its pharmacological properties and safety profile.
Check Digit Verification of cas no
The CAS Registry Mumber 594865-06-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,9,4,8,6 and 5 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 594865-06:
(8*5)+(7*9)+(6*4)+(5*8)+(4*6)+(3*5)+(2*0)+(1*6)=212
212 % 10 = 2
So 594865-06-2 is a valid CAS Registry Number.
594865-06-2Relevant articles and documents
Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors
Kim, Dong Chan,Lee, Yeo Ran,Yang, Beom-Seok,Shin, Kye Jung,Kim, Dong Jin,Chung, Bong Young,Yoo, Kyung Ho
, p. 525 - 532 (2007/10/03)
A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines 15-19, 30-38 capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biological evaluation was carried out and structure-activity relationship was examined. In our series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds. The compounds 33a,b having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds. In general, the unsubstituted compounds (30a,b, 33a,b, 36a,b) at N-1 possessed higher potency than the substituted compounds (32a,b, 34a,b) for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds didnot have a significant activity. The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine.
